BOLD
INSIDER BUYINSIDER SELLBoundless Bio, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeBoundless Bio agreed to merge with Serapha Bio in an all-stock deal (announced June 23, 2026) where BOLD shareholders will own only 3.7% of the combined entity trading as AATD, representing significant dilution. The company halted its Phase 1/2 POTENTIATE cancer trial in early 2026 due to market considerations, and reported Q1 2026 EPS that slightly beat consensus but disclosed only $92.8M cash runway, raising questions about standalone viability prior to the merger.
Red flags
- •Severe shareholder dilution: BOLD holders reduced to 3.7% ownership post-merger
- •Clinical pipeline setback: Phase 1/2 POTENTIATE trial halted in January 2026
- •Tight cash runway: $92.8M disclosed in Q1 2026 report, insufficient for independent operations
- •Ticker delisted: BOLD ceased trading following merger close and transition to AATD
- •Negative deal economics: Serapha raised $230M private placement at terms that heavily favor new investors over existing BOLD shareholders
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | — | SELL | 18K | $2.97 | $0.05M | 2026-08-26 | ↗ |
| TANG KEVIN | — | BUY | 3K | $2.44 | $0.01M | 2026-07-21 | ↗ |
| TANG KEVIN | — | BUY | 2K | $2.44 | $0.00M | 2026-07-20 | ↗ |
| TANG KEVIN | — | BUY | 265 | $2.44 | $0.00M | 2026-07-17 | ↗ |
| TANG KEVIN | — | BUY | 18K | $2.44 | $0.05M | 2026-07-16 | ↗ |
| TANG KEVIN | — | BUY | 2K | $2.44 | $0.00M | 2026-07-15 | ↗ |
| TANG KEVIN | — | BUY | 44K | $2.43 | $0.11M | 2026-07-14 | ↗ |
| TANG KEVIN | — | BUY | 48K | $2.42 | $0.12M | 2026-07-13 | ↗ |
| TANG KEVIN | — | BUY | 43K | $2.43 | $0.11M | 2026-07-10 | ↗ |
| TANG KEVIN | — | BUY | 7 | $2.48 | $0.00M | 2026-07-09 | ↗ |
| TANG KEVIN | — | BUY | 14K | $2.46 | $0.04M | 2026-07-08 | ↗ |
| TANG KEVIN | — | BUY | 16K | $2.48 | $0.04M | 2026-07-07 | ↗ |
| TANG KEVIN | — | BUY | 27K | $2.49 | $0.07M | 2026-07-06 | ↗ |
| TANG KEVIN | — | BUY | 10K | $2.49 | $0.02M | 2026-07-02 | ↗ |
| ARCH Venture Fund IX, L.P. | — | SELL | 16K | $2.49 | $0.04M | 2026-07-01 | ↗ |
| TANG KEVIN | — | BUY | 72K | $2.49 | $0.18M | 2026-07-01 | ↗ |
| CRANDELL KEITH | — | SELL | 16K | $2.49 | $0.04M | 2026-07-01 | ↗ |
| TANG KEVIN | — | BUY | 26K | $2.54 | $0.07M | 2026-06-30 | ↗ |
| TANG KEVIN | — | BUY | 100 | $2.50 | $0.00M | 2026-06-30 | ↗ |
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | — | 0.6% | -8.2% vs SPY -8.1% abs | 2026-08-14 | ↗ |